Syros Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA

Location

#3509

Growjo Ranking

Pharma

Industry

Estimated Revenue & Valuation

  • Syros Pharmaceuticals's estimated annual revenue is currently $21.4M per year.(i)
  • Syros Pharmaceuticals received $40.0M in venture funding in February 2018.
  • Syros Pharmaceuticals's estimated revenue per employee is $130,427
  • Syros Pharmaceuticals's total funding is $525.5M.
  • Syros Pharmaceuticals's current valuation is $162.3M. (January 2022)

Employee Data

  • Syros Pharmaceuticals has 164 Employees.(i)
  • Syros Pharmaceuticals grew their employee count by 14% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M344-2%$634MN/A
#2
$49.6M247-6%N/AN/A
#3
$10.7M53130%N/AN/A
#4
$20.1M10023%$113MN/A
#5
$4M48118%N/AN/A
#6
$1.8M4063%$538MN/A
#7
$40.2M200-11%N/AN/A
#8
$11.6M192-14%$506.4MN/A
#9
$3.7M4588%N/AN/A
#10
$4360M45081175%N/AN/A

Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros lead drug candidates are SY-1425, a selective RAR agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals

$525.5M

Total Funding

164

Number of Employees

$21.4M

Revenue (est)

14%

Employee Growth %

$162.3M

Valuation

N/A

Accelerator

Syros Pharmaceuticals News

2022-04-17 - Should You Buy Syros Pharmaceuticals Inc (SYRS) Stock After it Has Risen 8.08% in a Week?

Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and...

2022-04-17 - StockNews.com Downgrades Syros Pharmaceuticals ...

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and...

2022-04-06 - Syros Pharma Shares Rise; Says CDK12 Inhibitor Shows 'Strong Anti-Tumor Activity'

By Stephen Nakrosis. Shares of Syros Pharmaceuticals Inc. were up on the Nasdaq on Friday, after the company said preclinical data from its...

2019-10-17 - Syros eyes strategic shift after failure of hitherto promising cancer drug

Shares of Syros were down 32.3 percent on the Nasdaq following the news. The company has consequently decided to shift its focus from SY-1365 to another drug, the oral CDK7 inhibitor SY-5609, which it said inhibits CDK7 more selectively and potently than SY-1365 and in preclinical testing has s ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22.9M16420%$25.2M
#2
$18.4M164-4%N/A
#3
$15M164204%N/A
#4
$32.7M16510%N/A
#5
$26.5M16651%N/A

Syros Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2013-04-12$30.0MAARCH Venture Partners, Flagship VenturesArticle
2014-10-28$53.0MBArticle
2016-01-13$40.0MUndisclosedDeerfield Management CompanyArticle
2017-04-24$35.0MUndisclosedSamsara BioCapitalArticle
2018-02-01$40.0MUndisclosedJMP Securities LLCArticle